法莫蒂丁没有负面的内效应.

Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591.

Gastroenterology·1997

Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitis.

Clinical therapeutics·1995

Safety of acid-suppressing drugs.

Digestive diseases and sciences·1995

Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitis.

Alimentary pharmacology & therapeutics·1994

Efficacy of twice daily doses of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate to severe erosive esophagitis. Famotidine Erosive Esophagitis Study Group.

Scandinavian journal of gastroenterology·1993

Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group.

Archives of internal medicine·1991

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Mystery Client Methodologies to Evaluate Abortion Care and Access: A Scoping Review.

Healthcare (Basel, Switzerland)·2026

A Case of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Dysfunction, and Organomegaly (TAFRO) Syndrome Refractory to Treatment With Combination Therapy of Corticosteroid, Tocilizumab, and Rituximab: A Case Report.

Cureus·2026

Insertion of Subdermal Hormonal Implant May Trigger Complex Regional Pain Syndrome: A Case Report.

The Journal of adolescent health : official publication of the Society for Adolescent Medicine·2026

Diagnosis of chlamydial and gonococcal conjunctivitis: performance evaluation of a nucleic acid amplification test.

Microbiology spectrum·2026

Limited Availability of Short Tandem Repeat Genotype Testing in the United States for Diagnosis of Partial Hydatidiform Mole: A Dilemma for Practicing Precision Medicine.

The American journal of surgical pathology·2026

Intrauterine Pregnancy With a Correctly Positioned Levonorgestrel-Releasing Intrauterine System: A Case Report.

Cureus·2026

相关实验视频

法莫蒂丁没有负面的内效应.

相关概念视频

Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591.

Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitis.

Safety of acid-suppressing drugs.

Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitis.

Efficacy of twice daily doses of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate to severe erosive esophagitis. Famotidine Erosive Esophagitis Study Group.

Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Mystery Client Methodologies to Evaluate Abortion Care and Access: A Scoping Review.

A Case of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Dysfunction, and Organomegaly (TAFRO) Syndrome Refractory to Treatment With Combination Therapy of Corticosteroid, Tocilizumab, and Rituximab: A Case Report.

Insertion of Subdermal Hormonal Implant May Trigger Complex Regional Pain Syndrome: A Case Report.

Diagnosis of chlamydial and gonococcal conjunctivitis: performance evaluation of a nucleic acid amplification test.

Limited Availability of Short Tandem Repeat Genotype Testing in the United States for Diagnosis of Partial Hydatidiform Mole: A Dilemma for Practicing Precision Medicine.

Intrauterine Pregnancy With a Correctly Positioned Levonorgestrel-Releasing Intrauterine System: A Case Report.

相关实验视频

法莫蒂丁没有负面的内效应.

相关概念视频

相关文章